A Phase I Dose Escalation Safety Study of Subretinally Injected RetinoStat, a Lentiviral Vector Expressing Endostatin and Angiostatin, in Patients With Advanced Neovascular Age-Related Macular Degeneration
Latest Information Update: 03 Oct 2021
At a glance
- Drugs OXB 201 (Primary)
- Indications Age-related macular degeneration
- Focus Adverse reactions
- Acronyms GEM
- Sponsors Oxford BioMedica
- 03 Apr 2017 Status changed from active, no longer recruiting to completed.
- 05 May 2015 According to an Oxford BioMedica media release, results from this trial were presented at the Association for Research in Vision and Ophthalmology (ARVO) conference.
- 20 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 May 2015, as reported by ClinicalTrials.gov.